Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study

Mediterranean Journal of Rheumatology

article

Maria Pappa¹  Maria Kosmetatou²  Antonia Elezoglou³  Kyriaki Boki⁴  Pinelopi Konstantopoulou⁵  Charalampos Papagoras⁶  Alexandros Garyfallos⁷  Dimitrios Vassilopoulos⁸  Prodromos Sidiropoulos⁹  Petros Sfikakis¹  Dimitrios Boumpas²  George Bertsias⁹  Maria Tektonidou¹  Antonis Fanouriakis¹ 

[1] First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, "Laiko" General Hospital;Rheumatology Unit, Fourth Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, “Attikon” University Hospital;Department of Rheumatology, “Asklepieion” General Hospital;Rheumatology Unit, Sismanogleio General Hospital;Department of Rheumatology, “G. Gennimatas” General Hospital;First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace;Fourth Department of Internal Medicine, Aristotle University of Thessaloniki;Clinical Immunology-Rheumatology Unit, 2 nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens;Rheumatology and Clinical Immunology, University of Crete Medical School and University Hospital of Iraklio

关键词: lupus nephritis;    novel therapies;    belimumab;    voclosporin;    systemic lupus erythematosus;   

DOI  :  10.31138/mjr.33.2.263

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

Lupus nephritis (LN) affects a significant proportion of patients with systemic lupus erythematosus (SLE) and is characterised by increased morbidity and mortality. The updated joint EULAR/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations for the management of LN have set as target of therapy the optimisation (preservation or improvement) of kidney function, accompanied by a reduction in proteinuria of at least 25% by 3 months, 50% by 6 months, and below 500–700 mg/g by 12 months (complete clinical response). It is currently unknown what proportion of Greek patients with LN reach these proposed targets with the current available treatments. At the same time, recent successful phase 3 trials have led to the approval of both belimumab and voclosporin for the treatment of patients with LN and have steered discussions as to whether the “induction-maintenance” paradigm should be substituted by an early combination treatment for all patients. To inform future therapeutic decisions and facilitate the positioning of these new drugs in the therapeutic algorithm of LN, the current study protocol aims to map the unmet needs in the treatment of LN in Greece, by quantifying the proportion of patients who attain the recommended treatment targets in everyday clinical practice.

【 授权许可】

CC BY-NC